Levicept Reports Phase 2 Osteoarthritis Data

New LEVI-04 results from a 518-patient trial were presented at the ACR annual congress in Orlando.

Updated on Nov. 11, 2026 in Arthritis

A clear glass vial of pale amber liquid sits on a plain grey surface with a soft-focus laboratory bench behind it.
Levicept reported new phase 2 results for its investigational osteoarthritis drug LEVI-04 at the American College of Rheumatology congress in Orlando, from a 518-patient trial. AI Illustration. Upload story photo >

Levicept has reported new phase 2 results for LEVI-04 in osteoarthritis at the American College of Rheumatology annual congress in Orlando. The trial enrolled 518 patients and showed improvements in joint function compared with placebo, with the treatment described as well-tolerated.

Why it matters

Osteoarthritis has few systemic treatments, and Levicept says LEVI-04 could become the first new systemic option for the condition in over two decades. The data support a planned phase 3 programme for readers tracking treatments for joint disease worldwide.

The phase 2 trial enrolled 518 patients, and the results compare LEVI-04 with placebo on joint function and pain measures. Phase 3 outcomes and the size of the effect over longer treatment periods have not yet been reported.

The players

Levicept

Levicept is a small UK-based biotechnology company headquartered in Sandwich, developing LEVI-04 for osteoarthritis.

The details

LEVI-04 is a chimeric fusion protein that inhibits excess neurotrophin-3 while preserving nerve growth factor function and supplements p75NTR levels. In osteoarthritis, rising NT-3 is thought to amplify pain signals and drive joint breakdown, and an ex vivo study measured its effect on neurotrophin-3 in plasma samples from phase 2 patients.

Timeline

  1. Earlier this year: FDA accepted the LEVI-04 IND application.

  2. Earlier this year: Phase 2 data were published in The Lancet.

  3. November 11, 2026: Levicept presented new phase 2 results at the ACR annual congress in Orlando.

Health Landscape

LEVI-04 targets the neurotrophin imbalance in osteoarthritis rather than only symptoms, which distinguishes it from the mostly localized treatments used for the disease today. The phase 2 data place it in the early development pipeline for a condition with limited systemic therapies.

If LEVI-04 advances, it would offer people with osteoarthritis a potential systemic treatment rather than only localized options. Patients should continue to discuss current pain management choices with their clinicians, as the drug remains in clinical development.

The takeaway

Clinical progress on LEVI-04 shows researchers targeting the underlying biology of osteoarthritis rather than only its symptoms. Readers should watch for phase 3 results before expecting any change in treatment options.

Further reading

Explore more on Arthritis treatments and research.

Source note: This article includes information reported by Pharmaphorum.